कंपनी का अवलोकन
CeriBell, Inc. is a medical technology enterprise based in the United States that specializes in developing the Ceribell System, a point-of-care electroencephalography (EEG) platform engineered to address critical gaps in patient care within acute settings. The company further expands its portfolio by offering disposable, flexible headbands and other related medical devices to support its diagnostic ecosystem. Operating within the Healthcare sector and specifically the Medical Devices industry, CeriBell positions itself at the intersection of advanced diagnostics and acute care infrastructure. The firm currently commands a market capitalization of $699.00M and generates annual revenue of $89.06M, while employing a workforce of 327 individuals. These valuation and revenue metrics indicate that the company holds a significant but not dominant position in its niche, suggesting substantial capital deployment relative to its current sales output, which is typical for capital-intensive medical device developers requiring heavy investment in research, development, and regulatory approvals to scale production and market penetration.
वित्तीय स्वास्थ्य
CeriBell, Inc. reported a trailing twelve-month (TTM) revenue of $89.06M against a net income loss of $-53,412,000 and an EBITDA of $-57,061,000, revealing a substantial gap between top-line growth and bottom-line profitability that points to a cost structure dominated by high fixed costs, R&D expenditures, and potentially non-operating expenses. The company's free cash flow stands at $-23,596,500, which indicates a current state of negative cash generation that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing to fund operations. In terms of profitability margins, the firm maintains a robust gross margin of 87.9%, reflecting high pricing power or low cost of goods sold, yet this is heavily offset by an operating margin of -58.9% and a profit margin of -60.0%, signaling that overhead and operational expenses are consuming the vast majority of gross profits. The balance sheet shows a cash position of $159.26M compared to total debt of $22.28M, creating a conservative liquidity profile supported by a low debt-to-equity ratio of 14.34. This disparity between cash and debt suggests the company is not currently leveraged in a way that threatens solvency, allowing it to weather periods of negative earnings without immediate refinancing risks. Furthermore, a current ratio of 9.73 demonstrates exceptional short-term liquidity, indicating that the company holds nearly ten times more current assets than current liabilities, providing a wide buffer against short-term obligations. Return on Equity is -30.8% and Return on Assets is -17.3%, metrics that reveal management is currently unable to generate returns on shareholder capital or asset base, a common characteristic of early-stage or growth-focused medical device companies prioritizing expansion over immediate profit maximization.
मूल्यांकन आकलन
The valuation metrics for CeriBell, Inc. present a complex picture where the Trailing P/E Ratio is N/A due to negative earnings, while the Forward P/E is reported as -18.47, implying that the market anticipates a continued period of negative earnings before profitability is realized. The Price to Book ratio stands at 4.48, indicating that the market values the company at a significant premium over its book value, likely driven by intangible assets, intellectual property, and future growth potential rather than current tangible assets. Additionally, the Price to Sales ratio of 7.85 and an EV/EBITDA of -9.85 suggest that traditional multiple-based valuations are skewed by the negative earnings, forcing investors to rely on revenue multiples which place a high premium on the company's ability to scale sales in the medical device sector. The stock's trading range over the past year has oscillated between a 52-Week High of $24.33 and a 52-Week Low of $10.01, with the current price trajectory requiring contextual analysis of where it sits relative to this volatility. The Beta value is listed as N/A, meaning there is insufficient data provided to quantify the stock's price volatility relative to the broader market index, though the wide range between the high and low suggests inherent instability typical of small-cap healthcare stocks. These valuation figures collectively highlight that the market is pricing in aggressive growth expectations that must eventually translate into positive earnings to justify the current multiple levels.
Growth & Income
CeriBell, Inc. has demonstrated impressive top-line expansion with a Revenue Growth (YoY) of 33.7%, whereas the Earnings Growth (YoY) is N/A due to the company's ongoing net losses, indicating that revenue expansion is currently outpacing any potential for earnings turnaround in the absence of profitability. As a non-dividend payer, the company offers a Dividend Yield of N/A and a Payout Ratio of 0.0%, reflecting a strategy where earnings are not distributed to shareholders but are instead retained to fund operations and reinvest into growth initiatives such as product development and market expansion. Since the company does not distribute dividends, the entire focus of the financial profile is on capital appreciation and the potential future conversion of negative earnings into positive returns through operational efficiencies and market share gains. The overall growth and income profile is characterized by strong revenue acceleration coupled with significant cash burn, suggesting an investment thesis centered on high-risk, high-reward potential for a firm that has yet to achieve commercial profitability in its specialized acute care EEG platform.